Low risk of Pneumocystis jirovecii pneumonia and invasive aspergillosis in patients with Waldenström macroglobulinaemia on ibrutinib

Matthew P Cheng; Amanda E Kusztos; Joshua N Gustine; Scott L Dryden-Peterson; Toni E Dubeau; Ann E Woolley; Sarah P Hammond; Lindsey R Baden; Steven P Treon; Jorge J Castillo; Nicolas C Issa

doi:10.1111/bjh.15627

Low risk of Pneumocystis jirovecii pneumonia and invasive aspergillosis in patients with Waldenström macroglobulinaemia on ibrutinib

Br J Haematol. 2019 May;185(4):788-790. doi: 10.1111/bjh.15627. Epub 2018 Nov 20.

Authors

Matthew P Cheng^{1

2

3}, Amanda E Kusztos^{1

2}, Joshua N Gustine⁴, Scott L Dryden-Peterson^{1

2

3}, Toni E Dubeau⁴, Ann E Woolley^{1

2

3}, Sarah P Hammond^{1

2

3}, Lindsey R Baden^{1

2

3}, Steven P Treon^{3

4}, Jorge J Castillo^{3

4}, Nicolas C Issa^{1

2

3}

Affiliations

¹ Division of Infectious Diseases, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
² Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
³ Harvard Medical School, Boston, MA, USA.
⁴ Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA, USA.

PMID: 30460682
DOI: 10.1111/bjh.15627

No abstract available

Keywords: Pneumocystis jirovecii; Waldenstrom's macroglobulinaemia; aspergillosis; ibrutinib.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adenine / analogs & derivatives
Adult
Aged
Aged, 80 and over
Antineoplastic Agents / adverse effects*
Female
Humans
Invasive Fungal Infections / chemically induced*
Invasive Fungal Infections / prevention & control*
Male
Middle Aged
Piperidines
Pneumocystis carinii
Pneumonia, Pneumocystis / chemically induced*
Pyrazoles / adverse effects*
Pyrimidines / adverse effects*
Risk Factors
Waldenstrom Macroglobulinemia / drug therapy*

Substances

Antineoplastic Agents
Piperidines
Pyrazoles
Pyrimidines
ibrutinib
Adenine